AI Terminal
VERICI DX PLC
Director's Dealing • Dec 7, 2022
8005_dirs_2022-12-07_042c98e6-8dfa-4149-9d72-2fc87b54c469.html
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 8157I
Verici Dx PLC
07 December 2022
Verici Dx plc
("Verici Dx" or the "Company")
Director/PDMR Shareholding
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that Non-Executive Director Dr Lorenzo Gallon has been granted options to subscribe for up to 354,370 ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares"), at an exercise price of 20 pence per Ordinary Share, as part of his compensation (the "Options"). The Options were granted on 6 December 2022 are exercisable over three years from 9 May 2022.
Dr Lorenzo Gallon has no other holdings of Ordinary Shares or options in the Company.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Dr Lorenzo Gallon
2
Reason for the notification
a)
Position/status
Non-Executive Director
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Verici Dx plc
b)
LEI
213800FI5WE4FVQ3G645
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Options over ordinary shares of 0.1p each in Verici Dx plc
ISIN for Verici Dx plc Ordinary Shares GB00BM8HZD43
b)
Nature of the transaction
Grant of options over Ordinary Shares
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| Exercise price of 20 pence per share | 354,370 |
d)
Aggregated information
- Aggregated volume
- Price
N/A
e)
Date of the transaction
6 December 2022
f)
Place of the transaction
Outside a trading venue
Enquiries:
| Verici Dx | www.vericidx.com |
| Sara Barrington, CEO | Via Walbrook PR |
| Julian Baines, Chairman | |
| Singer Capital Markets (Nominated Adviser & Broker) | Tel: 020 7496 3000 |
| Aubrey Powell / Kailey Aliyar / Rachel Hayes | |
| Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] |
| Paul McManus / Sam Allen | Mob: 07980 541 893 / 07502 558 258 |
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHEAXAKEAAAFFA